Teva launches generic Epzicom

JERUSALEM — Teva Pharmaceutical on Wednesday announced the launch of its generic of Epzicom (abacavir and lamivudine). The drug is indicated to treat HIV-1 in combination with other retroviral agents. 

 

Teva’s generic will be available in 600-mg abacavir/300-mg lamivudine dosage strength. The drug had U.S. sales of about $449 million for the 12 months ending July 2016, according to IMS Health.